We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · August 24, 2020

The Influence of Lipid Metabolism on Survival Outcomes in Patients With mRCC Treated With TKIs

Japanese Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Japanese Journal of Clinical Oncology
The Influence of Dynamic Changes in Lipid Metabolism on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
Jpn. J. Clin. Oncol. 2020 Jul 28;[EPub Ahead of Print], X Zhang, H Zhang, J Dai, Z Liu, X Zhu, Y Ni, X Yin, G Sun, S Zhu, J Chen, J Zhao, J Wang, H Zeng, P Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading